摘要
远隔重洋,但是美国医改的通过依然对我国制药企业影响重大。在看到美国医改为我们带来利好消息的同时,以仿制为主的我国中小制药企业能否提高自身水平,抓住这一市场扩容的大好机会?
Separated by the Pacific Ocean,but the historic US medical reform bill that had been passed has an impact on China's pharmaceutical companies.With the good news that US medical reform brings to us,can small-and medium-sized China pharmaceutical companies that mainly involve in production of generic drugs improve their own capacities to seize the good opportunities form the market expansion?
出处
《中国处方药》
2010年第4期12-12,共1页
Journal of China Prescription Drug
